|
PTP4A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.75900005461705E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.06290000023712E-07 |
| Normal-vs-Stage2 |
2.061800E-02 |
| Normal-vs-Stage3 |
3.47460005212241E-09 |
| Normal-vs-Stage4 |
2.68580002682484E-09 |
| Stage1-vs-Stage2 |
2.029400E-01 |
| Stage1-vs-Stage3 |
1.413200E-01 |
| Stage1-vs-Stage4 |
1.376310E-02 |
| Stage2-vs-Stage3 |
4.613600E-02 |
| Stage2-vs-Stage4 |
1.181620E-02 |
| Stage3-vs-Stage4 |
3.737600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.35270033957613E-10 |
| Normal-vs-AfricanAmerican |
1.399030E-03 |
| Normal-vs-Asian |
1.42469999997452E-06 |
| Caucasian-vs-AfricanAmerican |
5.237000E-01 |
| Caucasian-vs-Asian |
7.209000E-01 |
| AfricanAmerican-vs-Asian |
3.983800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.58350000071195E-08 |
| Normal-vs-Female |
2.46719999985601E-08 |
| Male-vs-Female |
1.424960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.83569999978594E-07 |
| Normal-vs-Age(41-60Yrs) |
8.74140000384216E-08 |
| Normal-vs-Age(61-80Yrs) |
2.55200000021105E-07 |
| Normal-vs-Age(81-100Yrs) |
2.204200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.542200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.866000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.741800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.032600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.787600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.022000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.909790E-01 |
| Classical-VS-Follicular |
8.182600E-01 |
| Classical-VS-Other |
2.052200E-01 |
| Classical-VS-Normal |
4.55750004402233E-09 |
| Tall-VS-Follicular |
2.713800E-01 |
| Tall-VS-Other |
4.095600E-01 |
| Tall-VS-Normal |
4.62960000002788E-07 |
| Follicular-VS-Other |
3.679600E-01 |
| Follicular-VS-Normal |
2.026700E-04 |
| Other-VS-Normal |
2.835700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.19999999954091E-07 |
| Normal-vs-N1 |
1.8124000078501E-09 |
| N0-vs-N1 |
2.675600E-02 |
|
|
